In China, the chronic kidney disease (CKD) incidence rate is as high as 10.8%. Renal replacement therapy plays an critical role in the later stage of CKD and becomes mandatory, as end-stage renal disease (ESRD) is unavoidable in progressive CKD. Peritoneal dialysis (PD) has becoming an essential alternative treatment for patient with end-stage renal disease (ESRD). Hypertension is common among ESRD patients receiving PD treatment, with a prevalence rate of 80% -90%, It is major cause for cardiovascular related complications and deaths among ESRD patients. Therefore hypertension increases the cardiovascular disease risk among the patients of ESRD and at the same time plays an independent risk for the progression of ESRD. Most studies uses average blood pressure as a risk indicator, but in recent years, more evidence has shown that blood pressure variability (BPV), the degree of fluctuation of blood pressure for a long period, is an additional risk factors for cardiovascular events.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Difference between the coefficient of variation of mean daytime Systolic Blood Pressure from the baseline to the end of the study
Timeframe: Baseline/12Weeks
Difference between the Coefficient of variation of mean daytime Diastolic Blood Pressure from the baseline to the end of the study
Timeframe: Baseline/12Weeks
Difference between the Coefficient of Variation of mean nighttime Systolic Blood Pressure from the baseline to the end of the study
Timeframe: Baseline/12Weeks
Difference between the Coefficient of Variation of mean nighttime Diastolic Blood Pressure from the baseline to the end of the study
Timeframe: Baseline/12Weeks